These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 39017706)
1. Beyond cytotoxic potency: disposition features required to design ADC payload. Sun H; Wienkers LC; Lee A Xenobiotica; 2024 Aug; 54(8):442-457. PubMed ID: 39017706 [TBL] [Abstract][Full Text] [Related]
2. Antibody drug conjugates beyond cytotoxic payloads. Hobson AD Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349 [TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. Vezina HE; Cotreau M; Han TH; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650 [TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates Containing Payloads from Marine Origin. Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497 [TBL] [Abstract][Full Text] [Related]
5. Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. Li C; Menon R; Walles M; Singh R; Upreti VV; Brackman D; Lee AJ; Endres CJ; Kumar S; Zhang D; Barletta F; Suri A; Hainzl D; Liao KH; Lalovic B; Beaumont M; Zuo P; Mayer AP; Wei D Clin Pharmacol Ther; 2022 Oct; 112(4):754-769. PubMed ID: 34657311 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Malik P; Phipps C; Edginton A; Blay J Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691 [TBL] [Abstract][Full Text] [Related]
7. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class. Calopiz MC; Linderman JJ; Thurber GM Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Kamath AV; Iyer S Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773 [TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862 [TBL] [Abstract][Full Text] [Related]
10. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341 [TBL] [Abstract][Full Text] [Related]
11. Advances with antibody-drug conjugates in breast cancer treatment. Abdus Subhan M; Torchilin VP Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933 [TBL] [Abstract][Full Text] [Related]
12. ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs). Beaumont K; Pike A; Davies M; Savoca A; Vasalou C; Harlfinger S; Ramsden D; Ferguson D; Hariparsad N; Jones O; McGinnity D Xenobiotica; 2022 Aug; 52(8):770-785. PubMed ID: 36314242 [TBL] [Abstract][Full Text] [Related]
13. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038 [TBL] [Abstract][Full Text] [Related]
14. Payload diversification: a key step in the development of antibody-drug conjugates. Conilh L; Sadilkova L; Viricel W; Dumontet C J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546 [TBL] [Abstract][Full Text] [Related]
15. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes. Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822 [TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic considerations for antibody drug conjugates. Lin K; Tibbitts J Pharm Res; 2012 Sep; 29(9):2354-66. PubMed ID: 22740180 [TBL] [Abstract][Full Text] [Related]
18. Catabolism of antibody drug conjugates and characterization methods. Shadid M; Bowlin S; Bolleddula J Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386 [TBL] [Abstract][Full Text] [Related]
19. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates. Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988 [TBL] [Abstract][Full Text] [Related]
20. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects. Burton JK; Bottino D; Secomb TW AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]